Memorial Sloan Kettering Cancer Center’s Post

Innovative therapy forms such as immunotherapy, and particularly CAR-T cell therapy, revolutionize treatment for certain cancer diseases, as they demonstrate promising results in terms of cure rates and patients' quality of life. Current research of Dr. Anna Ossami Saidy from the Department of Hematology and Cell Therapy at Helios Klinikum Berlin-Buch GmbH centers around the potentials of CAR-T cell therapy for patients with central nervous system lymphoma. A patient group that was previously excluded from clinical trials. In a recent interview Dr. Ossami Saidy discussed her current work as well as her vision for the future of cancer treatment. Read the full interview here: https://lnkd.in/eaH7fGJw #Fresenius #CancerTherapy #CARTcelltherapy

In a groundbreaking development that marks a significant leap forward in cancer treatment, the FDA has recently given the green light to the first cell therapy designed to combat solid tumors. This innovative approach, known as Amtagvi or lifileucel, harnesses the power of the patient's own immune system, specifically TIL (tumor infiltrating lymphocytes) therapy, to fight advanced melanoma. Developed by Iovance, Amtagvi represents not just a new hope for patients with advanced melanoma but a monumental achievement nearly four decades in the making. The success of Amtagvi in a Phase 2 clinical trial has been particularly promising, with a remarkable 31% response rate among patients who had exhausted all other treatment options. This therapy stands out for its ability to offer sustained responses, with 42% of responding patients maintaining their response for 18 months or more. However, it's important to note that Amtagvi comes with challenges, including a high toxicity level and a price tag of $515,000, highlighting the complex balance between innovation and accessibility in the fight against cancer. TIL therapy, which involves extracting and amplifying cancer-fighting immune cells from the patient's tumor, represents a significant advancement over traditional methods, particularly in its application to solid tumors—a frontier where previous cell therapies like CAR-T have faced limitations. The approval of Amtagvi opens up a new era of cancer treatment, promising more personalized and effective options for patients battling solid tumors. As we celebrate this milestone, it's crucial to recognize the tireless efforts of researchers, clinicians, and patients who have contributed to this breakthrough. Amtagvi's success is a testament to the potential of cellular therapy to revolutionize cancer treatment, offering a beacon of hope for those facing advanced melanoma and paving the way for further innovations in the field. #CancerResearch #Immunotherapy #TILTherapy #FDAApproval #AdvancedMelanoma #CellTherapy #InnovationInCancer #PersonalizedMedicine #HealthcareBreakthrough #Amtagvi #SolidTumors 🔗 https://lnkd.in/evMtFxRj

Recent advancements in immunotherapy for inoperable liver cancer have demonstrated significant efficacy as a first-line treatment. 🌟 However, for patients whose condition worsens despite initial immunotherapy, standard treatment options remain limited. 🚫 A study led by Professor Changhoon Yoo explored the use of cabozantinib in these cases, revealing promising results with an average survival of 14.3 months when used as a second-line therapy and 6.5 months as a third-line option. 💡 Published in the prestigious 'Journal of Hepatology,' these findings underscore the potential of targeted therapies in managing advanced hepatocellular carcinoma. 📈 ✅ Click to read more https://lnkd.in/gpgm4xer

➡️Glioblastoma is an aggressive form of brain cancer with limited effective treatment options and a low survival rate (12-18 months after diagnosis). ➡️Glioblastoma is heterogeneous, implying not all cells within the tumor have the same antigen and each person's glioblastoma is unique. ➡️This makes targeting a particular protein an ineffective therapeutic approach. The uniqueness of glioblastoma also means treatment that works for one patient might not be effective in another patient. ➡️This lead researchers at the University of Pennsylvania to develop a CAR T cell therapy that targets two proteins commonly found in brain tumors—EGFR and IL13Rα2. ➡️The therapy proved effective in reducing tumor size in all patients in an ongoing phase I clinical trial. ➡️The main draw back was the neurotoxicity observed in all patients, but it is manageable. ➡️A wider range of patients would help determine and improve it's efficacy and safety since glioblastoma is a unique tumor.

CAR-T cell therapy offers hope to patients with non hodgkin's lymphoma (NHL). Data from a four year phase 3 clinical trial of axi-cel (Yescarta®), estimates that 55% of patients of patients would still be alive four years after receiving the therapy, compared with 46% of those who initially received the standard treatment for relapsed disease. “This is the first trial in nearly 30 years to significantly improve overall survival for patients with large B-cell lymphoma that is not responding to initial treatment or has relapsed,” Dr. Jason Westin, M.D., of the University of Texas MD Anderson Cancer Center. However, as the evidence behind the efficacy of CAR-T cell therapies grows and the transformative impact they can have on patients is realized, the reality is that not everyone who needs them can access these therapies. High costs, geographical barriers, and long vein-to-vein times are just a few of the many barriers limiting widespread patient access. At Ori, we’re on a mission to overcome these barriers so more patients can benefit from these potentially life changing therapies. Read more ➡️ https://lnkd.in/gkTVx8-B #manufacturingbrighterfutures #celltherapy #genetherapy #biotechnology #patientaccess

Armored CD19-directed CAR-T cells that a) are modified to secrete extracellular IL18 and b) are manufactured in just 3 days using UPenn's shorter manufacturing timelines are showing promise for patients who do not respond to (or relapse from) traditional CAR-T therapy. This is the future of #celltherapy.

🚨 Breaking News 🚨 In great news for cancer patients, Iovance Biotherapeutics, Inc. receives US FDA approval for their tumor-infiltrating lymphocyte (TIL) cellular #immunotherapy, which is likely the first in a series of approved solid tumor #celltherapy treatments. #immunology #immunooncology https://reut.rs/48tdkU0

As the first TIL therapy finally hits the clinic, the detection of tumor-infiltrating lymphocytes (TILs) in a reproducible, standardized, and rapid manner becomes all the more pertinent. Digital and automated approaches can diminish inter-observer variability and aid in the development of objective quantitation of TILs, helping better decision-making in cancers. #mlsalgorithm #TILs #digitalpathology #machinelearning #iqvia #q2solutions https://lnkd.in/eRZVhfQd

"Circulating tumor DNA analysis at the end of first-line treatment in patients with aggressive B-cell lymphoma had greater predictive value than a single PET-CT scan..." This is important for avoiding unnecessary tests and treatments, but also even more so for falsely believing a person is in remission. "In lymphoma, the standard method for evaluating treatment response is a PET-CT scan conducted upon completion of therapy. However, the positive predictive value of that method in determining whether the cancer has resolved following treatment is only about 50 percent... because a PET-CT scan can't measure disease at the molecular level and lacks specificity for lymphoma." "As an example, in more than 1,000 patients with diffuse large B-cell lymphoma in the GOYA clinical trial, 88 percent of patients were deemed to be in complete remission by PET scan, but 20 percent of those patients experienced subsequent disease progression." #data, #biotech, #healthcare, #biotechnology, #bioinformatics https://lnkd.in/ejVyHePg

Discover how bioimpedance spectroscopy (BIS) is revolutionizing post-breast cancer treatment! Learn about its role in early lymphedema detection and prevention to improve quality of life for breast cancer patients in survivorship https://lnkd.in/eeMEusaE #LymphedemaPrevention #HealthInnovation #CancerTreatment #LymphedemaManagement